Last reviewed · How we verify
The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer (REFIRM)
1. To evaluate the efficacy and safety of niraparib in Korean women with primary and recurrent epithelial ovarian cancer who underwent niraparib maintenance therapy 2. To evaluate the efficacy and safety of salvage niraparib therapy in Korean women with heavily pretreated epithelial ovarian cancer.
Details
| Lead sponsor | Asan Medical Center |
|---|---|
| Status | COMPLETED |
| Enrolment | 850 |
| Start date | Sun Dec 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Oct 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Epithelial Ovarian Cancer
Interventions
- Niraparib
Countries
South Korea